biotech
Connect Biotech Scales Back in China, Reassesses Strategy for Asthma Drug to Compete with Dupixent
Connect Biotech, China workforce reduction, Dupixent rival, asthma drug strategy, biotech industry
Unveiling the Future of Biotech: Top 11 Startups to Watch in 2024
Biotech startups, Top biotech companies, Biotechnology industry, Emerging biotech trends, Biotech innovation, Biotech awards
Catalent Reports Strong Q4 Results Amid Pending Acquisition by Novo Holdings
Catalent, Q4 Results, Novo Holdings, Acquisition, Pharmaceutical, Biotech, Consumer Health
WuXi AppTec Unfazed by BIOSECURE Act Threat, Secures New US Deals
WuXi AppTec, BIOSECURE Act, US Deals, Pharmaceutical Manufacturing, Biotech Industry
Novartis Partners with Dren Bio in $3 Billion Deal for Targeted Myeloid Engagers
Novartis, Dren Bio, Myeloid Engagers, Biotech, Pharmaceutical, Alliance, $3 Billion Deal
Canaan Partners Raises Additional $100M for Biotech Investments, Adds Pfizer Vet Uwe Schoenbeck
Canaan Partners, Biotech investments, Venture capital, Pfizer, Uwe Schoenbeck, Biopharma, Healthcare, Venture partner
George Church’s GRObio Secures $60 Million to Advance Gout Treatment into Clinical Trials
GRObio, George Church, Gout Treatment, Clinical Trials, Biotech Funding
Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market
Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures
VC Firm Oversees NGM Bio’s $122M Series A Funding After Taking it Private
NGM Bio, The Column Group, Venture Capital, Biotech, Series A Funding
Asceneuron Secures $100 Million in Series C Funding for Dementia Asset Development
Asceneuron, Series C Funding, Dementia Asset, Novo Ventures, Biotech Investment